Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) December 31, March 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 3,317 $ 6,518 Short-term investments 5,184 5,124 Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 as of March 31, 2024 and December 31, 2023 760 514 Inventories — current 1,831 1,958 Assets held for sale 15 51 Prepaid expenses and other current assets 535 807 Total current as ...

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q4 2023 Earnings Conference Call March 28, 2024 4:30 PM ET Company Participants T.J. Schaefer – Chief Financial Officer Stan Jacot – President and Chief Executive Officer Conference Call Participants Ben Klieve – Lake Street Capital Markets Dipesh Patel – H.C. Wainwright Operator Good afternoon and welcome to the Arcadia Biosciences Fourth Quarter and Full Year 2023 Financial Results and Business Highlights Conference Call. At this time all participants are in a liste ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) (cid:0) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR (cid:0) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37383 Arcadia Biosciences, Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-0571 ...

Exhibit 99.2 Arcadia Biosciences, Inc. Consolidated Balance Sheets (Unaudited) (In thousands, except share data) As of December 31, 2023 2022 Assets Current assets: Cash and cash equivalents $ 6,518 $ 20,644 Short-term investments 5,124 — Accounts receivable and other receivables, net of allowance for doubtful accounts of $0 and $3 as of December 31, 2023 and 2022, respectively 514 1,221 Inventories, net — current 1,958 2,321 Assets held for sale 51 87 Prepaid expenses and other current assets 807 795 Curre ...

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants T.J. Schaefer - Chief Financial Officer Stan Jacot - President and Chief Executive Officer Conference Call Participants Dipesh Patel - H.C. Wainwright & Co Ben Klieve - Lake Street Capital Markets Operator Good afternoon and welcome to Arcadia Biosciences Third Quarter 2023 Financial Results and Business Highlights Conference Call. [Operator Instructions] Please be advised that todayÂ’s ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-0571538 (State or other ju ...

Arcadia Biosciences, Inc. (NASDAQ:RKDA) Q2 2023 Earnings Conference Call August 10, 2023 4:30 PM ET Company Participants T.J. Schaefer - Chief Financial Officer Stan Jacot - President and Chief Executive Officer Conference Call Participants Ben Klieve - Lake Street Capital Markets Dipesh Patel - H.C. Wainwright Operator Good afternoon, and welcome to Arcadia Biosciences' Second Quarter 2023 Financial Results and Business Highlights Conference Call. At this time, all participants are in a listen-only mode. A ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-0571538 (State or other jurisdi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-37383 Arcadia Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 81-0571538 (State or other jurisd ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) (cid:0) ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR (cid:0) TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-37383 Arcadia Biosciences, Inc. (Exact name of Registrant as specified in its Charter) Delaware 81-0571 ...